市場調查報告書
商品編碼
966264

羥氯奎寧 (HCQ)的中國市場分析 (2020年∼2024年)

Investigation Report on Chinese Hydroxychloroquine(HCQ) Market, 2020-2024

出版日期: | 出版商: China Research and Intelligence | 英文 50 Pages | 商品交期: 最快1-2個工作天內

價格
  • 全貌
  • 簡介
  • 目錄
簡介

中國的羥氯奎寧的銷售額,2019年終達3億4030萬人民幣 (4930萬美元到) 。還有中國的生產量約55噸,大半在國內銷售、消費。羥氯奎寧是否可以幫助治療新的冠狀病毒感染(COVID-19)存在爭議,不過,受到COVID-19感染擴大趨勢,羥氯奎寧的需求也擴大。

本報告提供中國國內的羥氯奎寧 (HCQ) 市場相關分析,產品的概要和授權情形,整體市場規模趨勢預測 (過去、今後5年份),市場價格趨勢,主要的推動及阻礙市場要素,主要企業的簡介與市場佔有率,COVID-19的影響等資訊彙整,為您概述為以下內容。

目錄

第1章 羥氯奎寧的基本概念

  • 羥氯奎寧的適應症
  • 中國國內的羥氯奎寧發展歷史
  • 中國政府的羥氯奎寧的認證動向
  • COVD-19流行對羥氯奎寧市場的影響

第2章 中國國內的羥氯奎寧銷售趨勢

  • 中國國內的羥氯奎寧的銷售額 (2015年∼2019年)
    • 總銷售額 (2015年∼2019年)
    • 各地區的銷售額
  • 羥氯奎寧的銷售量
    • 總銷售量 (2015年∼2019年)
    • 各地區的銷售量
  • 中國國內的羥氯奎寧銷售趨勢:各劑型

第3章 中國的主要羥氯奎寧製造商

  • 主要廠商的市場佔有率
    • 市場佔有率:銷售額為基礎
    • 市場佔有率:銷售量為基礎
  • Sanofi
  • Shanghai Zhongxi Pharmaceutical Co., Ltd.
    • 企業簡介
    • 中國國內的羥氯奎寧銷售趨勢

第4章 中國國內的羥氯奎寧的價格趨勢

  • 中國國內的羥氯奎寧的平均價格
    • 中國國內的平均價格
    • 各地區的平均價格
  • 羥氯奎寧的價格趨勢:各主要製造商
    • Sanofi
    • Shanghai Zhongxi Pharmaceutical Co., Ltd.

第5章 中國的羥氯奎寧市場未來展望

  • 中國的羥氯奎寧影響市場的要素
    • 市場促進因素和機會
    • 威脅與課題
  • 中國國內的羥氯奎寧的市場規模,預測值 (2020年∼2024年)
  • 競爭格局的預測
  • 中國的羥氯奎寧的出口趨勢
目錄
Product Code: 2010438

Hydroxychloroquine(HCQ) is an antimalarial drug. It treats malaria by killing the parasites that cause the disease. Hydroxychloroquine was listed in the United States in 1955, and the original research drug manufacturer was Sanofi. Hydroxychloroquine has been listed in Canada, France, Germany, Australia, China, Japan and other countries, and many companies worldwide have produced generic drugs of hydroxychloroquine. The indications for hydroxychloroquine include malaria, rheumatoid arthritis, lupus erythematosus, etc.

According to CRI, in 2019, the global production volume of hydroxychloroquine was approximately 300 tons. Among them, India produced about 110 tons, ranking first. The total production volume in Europe is about 80 tons, of which Sanofi's production is about 60 tons, and Novartis's Sandoz production is about 20 tons. Hydroxychloroquine produced in Europe is mainly sold to Europe and Asia. China's production is about 55 tons, most of which are sold in China. In 2020, China exported about 20 tons of hydroxychloroquine APIs. The hydroxychloroquine preparations on the global market are basically hydroxychloroquine sulfate preparations. In 2019, the world's most important hydroxychloroquine market was the United States, which consumed approximately 90 tons of hydroxychloroquine APIs, and the main source of imports was India. India is the world's second largest market, consuming approximately 60 tons of APIs. The Chinese market consumes approximately 35 tons of APIs.

It is not fully understood how this drug works to treat lupus erythematosus or rheumatoid arthritis. However, it is believed that this drug affects how your immune system works, which may be a benefit in lupus erythematosus and rheumatoid arthritis.

On March 28, 2020, FDA issued an EUA to allow hydroxychloroquine sulfate and chloroquine phosphate donated to the Strategic National Stockpile (SNS) to be distributed and used for hospitalized COVID-19 patients. An EUA allows for an unapproved drug to be prescribed in limited and controlled ways during an emergency such as a pandemic.

There is a lot of controversy over whether hydroxychloroquine can prevent, treat, or cure COVID-19, the illness caused by the novel coronavirus. Some small studies in China and Europe were initially promising, however, other studies have found that hydroxychloroquine offers no benefit or may even be harmful to patients infected with the coronavirus. There are many more studies underway, but the best available evidence suggests that hydroxychloroquine is not effective in the treatment and prevention of COVID-19, and the potential benefits of the drug do not outweigh the known and potential risks. As a result, on June 15, 2020, the FDA has revoked their earlier issue of an Emergency Use Authorization (EUA) for hydroxychloroquine.

According to CRI's market research, as of the end of 2020, only two companies in the Chinese market have been approved for hydroxychloroquine, namely Sanofi, the original research drug manufacturer of hydroxychloroquine, and Shanghai Zhongxi Pharmaceutical Co., Ltd., a generic drug manufacturer.

According to CRI's market research, in 2019, the sales value of Hydroxychloroquine reached CNY340.3 million(US$49.3 million) in China. As Shanghai Zhongxi Pharmaceutical Co., Ltd.'s hydroxychloroquine product has a certain price advantage, it has occupied a major share of the Chinese market. In 2019, based on sales value, Shanghai Zhongxi Pharmaceutical Co., Ltd.'s hydroxychloroquine accounted for 69% of the Chinese market.

As some studies have shown that hydroxychloroquine may have a certain effect on COVID-19, the demand for hydroxychloroquine in the global market will increase in 2020-2021. According to CRI's market research, from January to August 2020, China's exports of hydroxychloroquine increased by approximately 20% year-on-year. It is expected that China's domestic hydroxychloroquine market sales will continue to grow from 2020 to 2024, and China's hydroxychloroquine export value will also continue to rise.

Topics Covered:

  • The impact of the COVD-19 epidemic on the hydroxychloroquine market
  • Development environment of Chinese Hydroxychloroquine market
  • Sales value and volume of Hydroxychloroquine in China 2015-2019
  • Sales value and volume of Hydroxychloroquine in Different Regions of China 2015-2019
  • Prices of Hydroxychloroquine in China 2015-2019
  • Prices of Sanofi's Hydroxychloroquine(Plaquenil) in Different Regions of China 2015-2019
  • Prices of Shanghai Henlius Biotech, Inc.'s Hydroxychloroquine(Fenle) in Different Regions of China 2015-2019
  • Progress of Generic Hydroxychloroquine in China
  • Prospects of Chinese Hydroxychloroquine Market, 2020-2024

Table of Contents

1 Basic Concepts of Hydroxychloroquine

  • 1.1 Indications for Hydroxychloroquine
  • 1.2 Development History of Hydroxychloroquine in China
  • 1.3 Governmental Approval of Hydroxychloroquine in China
  • 1.4 The impact of the COVD-19 epidemic on the hydroxychloroquine market

2 Sales of Hydroxychloroquine in China, 2015-2019

  • 2.1 Sales Value of Hydroxychloroquine in China 2015-2019
    • 2.1.1 Overall Sales Value of Hydroxychloroquine in China 2015-2019
    • 2.1.2 Sales Value of Hydroxychloroquine in Different Regions of China
  • 2.2 Sales Volume of Hydroxychloroquine
    • 2.2.1 Overall Sales Volume of Hydroxychloroquine in China 2015-2019
    • 2.2.2 Sales Volume of Hydroxychloroquine in Different Regions of China
  • 2.3 Sales of Hydroxychloroquine by Dosage Form in China

3 Major Hydroxychloroquine Manufacturers in China, 2015-2019

  • 3.1 Market Share of Major Hydroxychloroquine Manufacturers in China
    • 3.1.1 Market Share by Sales Value
    • 3.1.2 Market Share by Sales Volume
  • 3.2 Sanofi
    • 3.2.1 Enterprise Profile of Sanofi
    • 3.2.2 Sales of Sanofi's Hydroxychloroquine in China
  • 3.3 Shanghai Zhongxi Pharmaceutical Co., Ltd.
    • 3.3.1 Enterprise Profile of Shanghai Zhongxi Pharmaceutical Co., Ltd.
    • 3.3.2 Sales of Shanghai Zhongxi Pharmaceutical Co., Ltd. 's Hydroxychloroquine in China

4 Prices of Hydroxychloroquine in China, 2019-2020

  • 4.1 Average Prices of Hydroxychloroquine in China
    • 4.1.1 Average Price of Hydroxychloroquine in China
    • 4.1.2 Average Price of Hydroxychloroquine in Different Regions of China
  • 4.2 Prices of Major Manufacturers' Hydroxychloroquine in China
    • 4.2.1 Price of Sanofi's Hydroxychloroquine(Plaquenil) in China
    • 4.2.2 Price of Shanghai Zhongxi Pharmaceutical Co., Ltd. 's Hydroxychloroquine(Fenle) in China

5 Prospects of Chinese Hydroxychloroquine Market, 2020-2024

  • 5.1 Factors Influencing Hydroxychloroquine Development in China
    • 5.1.1 Driving Forces and Market Opportunities
    • 5.1.2 Threats and Challenges
  • 5.2 Forecast on Market Size of Hydroxychloroquine in China 2020-2024
  • 5.3 Forecast on Competition Pattern
  • 5.4 Export of China's Hydroxychloroquine

Table of Selected Charts

  • Chart Hydroxychloroquine Products Approved to Market in China by 2020
  • Chart Sales Value of Hydroxychloroquine in China, 2015-2019
  • Chart Sales Value of Hydroxychloroquine by Region in China, 2015-2019
  • Chart Sales Volume of Hydroxychloroquine by Region in China, 2015-2019
  • Chart Market Share of Hydroxychloroquine Manufacturers by Sales Value in China, 2015-2019
  • Chart Sales Value and volume of Sanofi's Hydroxychloroquine in China, 2015-2019
  • Chart Sales Value and volume of Shanghai Zhongxi Pharmaceutical Co., Ltd. 's Hydroxychloroquine in China, 2015-2019
  • Chart Prices of Sanofi's Hydroxychloroquine(MabThera/ Rituxan) in Different Regions of China, 2019-2020
  • Chart Prices of Shanghai Zhongxi Pharmaceutical Co., Ltd. 's Hydroxychloroquine(Rituxan) in Different Regions of China, 2019-2020
  • Chart Forecast on Sales of Hydroxychloroquine in China, 2020-2024
  • Chart Generic Drugs of Hydroxychloroquine in China by 2020